PMCB (PharmaCyte Biotech) Short Interest


PMCB PharmaCyte Biotech Inc PMCB
32 GF Score
Price $0.76
! 2 Warning Signs
View Full Analysis

What is PharmaCyte Biotech Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

PMCB vs IMNN, ACXP, ENVB: Short Interest Comparison

For the Biotechnology subindustry, PharmaCyte Biotech's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmaCyte Biotech Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's Short Interest distribution charts can be found below:

* The bar in red indicates where PharmaCyte Biotech's Short Interest falls into.


PMCB
32GF Score
PharmaCyte Biotech Inc PMCB
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaCyte Biotech Business Description

Address 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
32GF Score

Get the complete analysis for PMCB

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.76
Price